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Purpose: To assess if intensity-modulated radiotherapy (IMRT) can possibly lead to improved local control and
lower incidence of vision impairment/blindness in comparison to non-IMRT techniques when treating sinonasal
malignancies; what is the most optimal dose constraints for the optic pathway; and the impact of different IMRT
strategies on optic pathway sparing in this setting.
Methods and materials: A literature search in the PubMed databases was conducted in July, 2012.
Results: Clinical studies on IMRT and 2D/3D (2 dimensional/3 dimensional) RT for sinonasal malignancies suggest
improved local control and lower incidence of severe vision impairment with IMRT in comparison to non-IMRT
techniques. As observed in the non-IMRT studies, blindness due to disease progression may occur despite a lack of
severe toxicity possibly due to the difficulty of controlling locally very advanced disease with a dose ≤ 70 Gy.
Concurrent chemotherapy’s influence on the the risk of severe optic toxicity after radiotherapy is unclear. A
maximum dose of ≤ 54 Gy with conventional fractionation to the optic pathway may decrease the risk of
blindness. Increased magnitude of intensity modulation through increasing the number of segments, beams, and
using a combination of coplanar and non-coplanar arrangements may help increase dose conformality and optic
pathway sparing when IMRT is used.
Conclusion: IMRT optimized with appropriate strategies may be the treatment of choice for the most optimal local
control and optic pathway sparing when treating sinonasal malignancy.
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Being less than 1% of all cancer, sinonasal malignancies
frequently present in the locally advanced stage [1,2].
This poses a therapeutic challenge in the treatment plan-
ning and delivery of definitive or adjuvant radiotherapy
due to the proximity of the primary tumors to critical
normal structures, such as the optic nerves (ON) and
chiasm (OC). Severe vision impairment and blindness
are often encountered after therapeutic doses were deliv-
ered in the pre-IMRT era [3-19]. This was most com-
monly observed in the era of conventional radiotherapy
(2D), when doses to the target volume and adjacent* Correspondence: achiaz2010@gmail.com
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reproduction in any medium, provided the orcritical structures could not be well defined [3-9,14-19].
Due to the lack of the ability to deliver a highly con-
formal radiation dose, the clinical outcome in the 2 D
era is also poor [3-9]. As an ideal approach to deliver a
meaningful dose to the primary tumor or the postopera-
tive tumor bed, and optimally preserve the optic path-
way, which is often immediately adjacent to the planning
target volume (PTV), intensity modulated radiotherapy
(IMRT) has been utilized with excellent short term
results [20,21]. Since the adaptation of IMRT into clin-
ical practice, the clinical outcome of IMRT for sinonasal
malignancies have been reported by many institutions
with improved visual preservation [22-26]. However,
there was no consensus on the dose limits for optimal
visual preservation. Thus, we conduct this review to
analyze if the incidence of vision impairment and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conventional/three dimensional conformal radiotherapy
(3D-CRT) when treating sinonasal malignancies and
local tumor control follow IMRT when compared with
non-IMRT techniques; the relationship of vision impair-
ment and radiation dose to the optic pathway in this
setting; and how various strategies of IMRT delivery
may influence optic structure sparing.
Methods and materials
This systematic review of literature was to investigate
the clinical outcome and the incidence of vision impair-
ment and blindness relative to the doses to the optic
pathway after 2D RT, 3D-CRT, and IMRT for sinonasal
malignancies in order to demonstrate if IMRT can
potentially lower the incidence of vision impairment
without any compromise of tumor control. In addition,
we will explore the potential advantages & disadvantages
of various IMRT delivery strategies for optic pathway
sparing in this setting. A search based on PubMed elec-
tronic databases was conducted in July, 2012 to select
studies outlining the following: clinical outcome of
radiotherapy for sinonasal or paranasal malignancies;
vision impairment and blindness after radiotherapy. The
following terms were explored and used for each data-
base search: sinonasal malignancies, paranasal sinus
tumors, nasal cavity & ethmoid sinus tumors, vision
impairment, optic neuropathy, optic retinopathy, blind-
ness, radiotherapy, IMRT. For clinical reports, only the
most complete and most recently published full length
study reporting the clinical outcome and treatment
related toxicity after 2D/3D RT, IMRT, or any combin-
ation of them for predominantly carcinomas from the
sinonasal complex has been selected from any one insti-
tution. Two separate studies from one single institution
were selected only if they described the outcome after
RT delivered with two different techniques, or when one
is reporting the outcome for exclusively one RT delivery
approach and another is a comparison study of clinical
outcome after RT delivered with various techniques.
Studies describing the technical aspects of RT delivery
were selected as long as the same investigation was not
duplicated by the same group of authors. Conventional
fractionation of 1.8 to 2 Gy per day is assumed unless
otherwise indicated in this study.
Results
Fifteen studies published between 1983 and 2009 [3-17],
describing the clinical outcome and optic toxicity in
detail after 2D or 3D RT; 2 studies published between
2008 & 2009 [18,19], reporting the clinical outcome &
optic toxicity profile after RT delivered with a combin-
ation of 2D/3D RT & IMRT; 5 studies published be-
tween 2006 and 2012 [22-26], reporting the clinicaloutcome & optic toxicity after exclusively IMRT; and 3
studies published between 2007 and 2012 comparing the
clinical outcome & incidence of optic toxicity after
IMRT and non-IMRT techniques [27-29] were selected
for the clinical portion of this review. Twelve studies
describing the technical aspects of IMRT for paranasal
malignancies were also selected for exploration of what
would be the best approach to optimize optic pathway
sparing [30-41].
Local control & optic toxicity when IMRT is not used, or
used in only a portion of patients
As shown in Table 1, treatment related blindness has
been reported in all but one study which delivered a
median dose of 54 Gy in 27 daily fractions when only
2D RT was delivered [3-9]. The local control from stud-
ies which reported them was 45.4%–62% (Table 1). The
lowest local control was associated with a relatively high
percentage of T4 disease and lower dose delivered with
a hypofractionated course [6].
The local control reported in the four 3D studies was
56.4%–83%, while the percentage of locally advanced
disease appear to be high when compared with that
reported in the 2D studies [10-13] (Tables 1 and 2). The
incidence of treatment related blindness appears to be
lower in these studies. Only 1 such case was found
3 years after radiotherapy [12]. However, 41.2% patients
experienced severe optic toxicity at 2 years after being
treated with concurrently intra-arterial cisplatin and
radiotherapy in one study [10]. This study also reported
the best local control of 83% after a median follow up of
55.2 months.
Severe vision impairment/blindness became more
prevalent in studies that included patients who received
2D RT and those who were treated with 3D and/or
IMRT [14-19] (Table 3). The local control in these stud-
ies was 35.9%–64.4%. The lowest local control (35.9%)
was found in a study which only included patients with
unresectable T4b disease treated to 70 Gy [18]. Other-
wise, the local control was 58.5%–64.4% in these studies.
It was 62% in the study which observed blindness due to
disease progression only [16]. 56.67% of the patients had
T4 disease on that study. A study that reported both 2D
& 3D results demonstrated the actuarial rate of severe
ophthalmological complications at 5 years to be 15%
after 2D RT, but only 4% after 3D CRT even though this
did not reach any statistical significance [15]. In the 2
studies which included 2D/3D RT, and IMRT, blindness
is found 7 years after IMRT in one study when an area
of the optic nerve received 77 Gy; and mostly after a
definitive dose of 70 Gy/35 daily fractions was delivered
in the other study [18,19].
As shown in several studies, the incidence of vision
impairment appears to correlate with the radiation dose
Table 1 Optic toxicity after 2D RT for sinonasal malignancies
Ref. # Median follow
up (mo)
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219 n/a n/a 2D n/a n/a Retina: 58.3
Gy/29 frxǂ.
Ipsilateral: 33.7%. 8.2% ipsilateral blindness
due to optic neuropathy;
bilateral blindness due to












44–60 Gy (56 Gy);
34% when optic
nerve received












171 ~ 60 n/a 2D 50-70
Gy/25–35 frx








2D 42-72 Gy, 2
Gy daily or bid
delivered with
Co-60 or electrons
56% n/a n/a 13.6% (3/22) blindness




30 n/a n/a 2D 34-86 Gy, various
fractionation
n/a n/a 6.7% (after 65
Gy received)
6.7% who received >
68 Gy
# number of patients, n/a not available, frx fraction, †postoperative only, *associated with vision impairment or blindness, ON optic nerve, OC optic chiasm, ǂ
median dose, ¶ average dose, pt patient, chemotherapy in a portion of pts§.
Chi et al. Journal of Hematology & Oncology 2013, 6:4 Page 3 of 10
http://www.jhoonline.org/content/6/1/4received by the optic pathway [5,9,11-16]. The incidence
of vision impairment appeared to be low when the optic
pathway has received less than 60 Gy. As shown by Jiang
et al. the 10 year incidence of optic neuropathy was
2.3% when the optic nerve (ON) received 44–60 Gy,
which increased to 34% when the dose to the optic
nerve was 61–78 Gy [5]. Optic chiasm injury, which led
to bilateral blindness, increased from 8% to 24% when
the OC dose increased from 50–60 Gy to 61–76 Gy [5].
In other studies, severe vision impairment/blindness was
also more commonly found when radiation dose to the
optic apparatus exceeded 60 Gy [9,13-15]. However, only
1 case of radiation related blindness was reported when
the ON/OC dose was limited to < 54 Gy [11,12,16].
Among all seventeen studies, a low incidence of blind-
ness due to disease progression was observed in two
studies that reported outcome after 3D RT alone and
2D/3D RT [11,16]. Both studies did not report any treat-
ment related vision impairment.
Chemotherapy was combined with RT (2.6%–100% of
the patients in each study, mostly < 50%) predominantlyin a sequential fashion in multiple studies [3,5-7,10-
12,14-18]. In these studies, the effect of chemotherapy
on RT-related vision impairment has not been well
described other than the fact concurrent chemo-radiation
as reported by Homma et al. has been associated with a
high incidence of severe optic toxicity [10].
Local control & optic toxicity after IMRT
Among the 5 studies [22-26] which reported the clinical
outcome & toxicity profile after IMRT for sinonasal ma-
lignancies, no treatment related blindness was observed.
Local control varied from 63.9% to 81% (Table 4).
As shown in Table 4, no severe optic toxicity was
reported when the dose to the ON/OC was kept to
≤ 54 Gy (conventional fractionation). However, because
of the short follow-up, and the relatively small number
of patients, it remains to be seen whether 54 Gy is the
dose limit for optimal visual preservation. Late severe vi-
sion impairment of 1.4% was observed when < 5% of the
optic pathway was allowed to receive ≥ 60 Gy [22]. Se-
vere vision impairment due to tumor invasion is also
Table 2 Optic toxicity after 3D RT for sinonasal malignancies
Ref. # Median follow
up (mo)







3D 65 Gy/26 frx or
70 Gy/35 frx
83.0% n/a 42.1% grade 3 or 4
optic toxicity at 2 years
(CTCAE v.3); severe optic









61.3% ON: None 2 due to disease
progression, 1 due















80% ON: None 1 patient 3 years













56.4% n/a 1 retinal artery occlusion
and 1 optic neuropathy





# number of patients, n/a not available, frx fraction, †postoperative, *associated with vision impairment or blindness, ON optic nerve, OC optic chiasm, ǂ median
dose, ¶ average dose, pt patient, chemotherapy in a portion of pts§.
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70 Gy. When compared with 3D or 2 D RT delivered at
the same institution during an earlier era, three studies
demonstrated noticeably improved clinical outcome and
lower incidences of vision impairment and blindness
after IMRT (Table 5).
Among IMRT-only studies, 16% & 56% of the patients
in studies by Hoppe et al. & Wieger et al. respectively,
have received chemotherapy as well [25,26]. In the IMRT
vs. non-IMRT studies, 35.4% and 15% of the patients
reported by Al-Mamgami et al. & Chen et al. received
chemotherapy [28,29]. No clear effect of chemotherapy
on vision impairment after RT was observed in these
studies.
Technique of IMRT delivery for the treatment of sinonasal
malignancy
Among the 6 small studies [30-35] comparing IMRT and
2D/3D RT, IMRT was found to produce more conformal
target volume coverage and/or improved sparing of optic
structures when compared to non-IMRT techniques by
some (Table 6). As shown by Claus et al. different IMRT
strategies can lead to differences in PTV coverage and
OAR sparing in the treatment of sinonasal malignancies
[36]. Non-coplanar set up, increased number of beams& segments may lead to better target volume coverage
and ON/OC sparing. Four studies further compared spe-
cific IMRT strategies [37-40]. Their findings are also
described in Table 6. Although no differences between
5-beam coplanar & non-coplanar IMRT in OAR sparing
or target volume was shown by Serre et al. [38], partially
non-coplanar IMRT has been shown to improve target
volume dose coverage and sparing of optic structures
when compared with 9-beam coplanar IMRT with Wang
et al. [37]. An advanced technique of IMRT delivery
under image guidance, helical tomotherapy (HT), was
shown to be mostly comparable to 7-beam non-coplanar
IMRT in ON/OC sparing, but superior in target dose
homogeneity by Sheng et al. when a preoperative dose
of 50 Gy was prescribed [39]. On the contrary, it was
shown to generate both superior target dose homogen-
eity and optic structure sparing when compared to 9–11
beam coplanar IMRT in delivering 70 Gy/35 fractions by
Chen et al. [40].
At last, the importance of incorporating clinical deci-
sion into the IMRT optimization process was demon-
strated by Tsien et al. [41]. In their study to deliver
70 Gy, the decision to spare only the contralateral optic
pathway led to noticeably improved PTV coverage when
compared to 3D CRT, which may result in better tumor
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retinopathy in 1 pt
















70 Gy/35 frxǂ 35.9% n/a 1 case of Optic



































# number of patients, n/a not available, frx fraction, †postoperative, *associated with vision impairment or blindness, ON optic nerve, OC optic chiasm, ǂ median
dose, ¶ average dose, pt patient, chemotherapy in a portion of pts§.
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which were optimized to spare bilateral optic pathways.
Discussion
To our best knowledge, this is the first systematic re-
view that investigates the clinical outcome and the level
of optic pathway sparing after IMRT in comparison to
2D/3D RT for sinonasal malignancies. As described
above, worse local control and high incidence of severeoptic toxicity are mostly found after 2D RT (Tables 1, 2,
3 and 4). Improved local control and lower incidence of
severe vision impairment was found after 3D CRT and
IMRT, with IMRT being associated with the better local
control and lower incidence of severe vision impairment
in general (Tables 2, 4 and 5). As shown by Dirix et al.
statistically significantly improved 2-year DFS and no-
ticeably better toxicity profile was found following
IMRT when compared with patients who were previous
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treated pts; 2.7% grade 3 impairment
due to tumor invasion in both non-
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PTV1 70 Gy 72.9% ON/OC
constraint: <
54 Gy.
No RTOG grade 3–4 toxicity None
PTV2 60 Gy Actual Dmax:
PTV3 54 Gy ON










High risk PTV 66 Gy/33 frx,
74.4 Gy, 1.2 Gy bid in 5 pts;
SRS/SRT bst in 4 pts: 8 Gy x
1 frx or 5 Gy x 2 frx
75% ON/OC
constraint:
45 Gy, 63 Gy if
treated with bid
schedule.
1 grade 3 optic neuropathy related to







#: number of patients, *PTV1: residual disease, PTV2: surgical bed/areas at high risk for microscopic involvement, PTV3: elective nodal regions; n/a not available; ǂ
median dose; ¶ average dose; ON optic nerve; OC optic chiasm; pts patients.
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not statistically significant, improved local control in
two other studies which compared IMRT and 3D and/or
2D RT were also seen, while one of them also demon-
strated statistically significant improvement in opticorgan preservation with IMRT over 3D CRT [28,29].
Further improvement in treatment outcome may lay
in combining IMRT with newer class of systemic agents
as those found in the treatment of other malignancies
[42-45].
Table 5 Optic sparing, IMRT vs. non-IMRT
Ref. Dose Clinical outcome Dose to optic structures Vision impairment
Dirix [27] 60-66 Gy/30–33 frx for
both IMRT and 3D-CRT
LC: 76% vs. 67% at 2 yrs
favoring IMRT (p = 0.06);
ON/OC constraint: ≤ 60 Gy for
IMRT.
No vision impairment after IMRT
DFS: 72% vs. 60% at 2 yrs
favoring IMRT (p = 0.02)
15.8% radiation induced retinopathy after
3D CRT.
OS: 89% vs. 73% at 2 yrs




IMRT(70%): 60–74 Gy LC: 80% for IMRT & 64% for
3D CRT (p = 0.2)
Dmaxǂ (IMRT vs. 3DCRT) when
70 Gy/35 frx was prescribed:
Ocular toxicity: 32% after 3DCRT, 5% after
IMRT (p < 0.0001)
3DCRT(30%): 60–70 Gy OC 47 Gy vs. 54 Gy Blindness: 1 after IMRT, 3 after 3DCRT
ON Organ preservation 88% vs. 65% favoring
IMRT (p = 0.01)
-Ipsilateral 50 Gy vs. 56 Gy
-Contralateral 42 Gy vs. 48 Gy
Chen [29] 2D 50–74 Gy LC: n/a ≥ RTOG grade 3 visual toxicity
3D 50–73 Gy 2D: 55.9% -2D 20%
IMRT 66–72 Gy 3D: 67% -3D 9%
IMRT: 69.6% -IMRT 0%
Blindness is only observed after 2D RT only
(5.1% of pts treated with 2D RT)
ON optic nerve, OC optic chiasm; ǂ median dose; n/a not available; pt patient.
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were reported in two studies [11,16]. No severe treat-
ment related vision impairment was reported while a
local control of approximately 60% was achieved in both
studies. This may be due to the difficulty of controlling
locally very advanced disease. These studies included
38.7% and 56.67% of T4 disease, yet none had patients
receiving more than 70 Gy [11,16]. The local control
rate after definitive RT delivered with mostly non-IMRT
techniques [11,14,18,19] has been poor in general, espe-
cially for T4b disease even when a dose of 70 Gy was
given [18]. Thus, a higher dose than previously used
may need to be used when treating very locally advanced
disease, with sacrificing the ipsilateral optic pathway
being considered. On the other hand, superior conformal
avoidance of the optic structures with IMRT may improve
the outcome of definitive RT for sinonasal malignancies.
This is evidenced by Wiegner et al. who observed a local
control of only 60% after definitive IMRT delivering the
conventionally accepted dose in a cohort of patients
among whom 76% had T4 disease [26].
A high incidence of severe optic toxicity was observed
following concurrent intra-arterial chemotherapy and
3D RT as shown by Homma et al. despite the excellent
local control of 83% achieved in their study [10]. Thus,
concurrent chemotherapy, such as intra-arterial cisplatin
in this study, may potentially be a contributing factor to
severe optic toxicity after radiotherapy for sinonasal ma-
lignancies. Such high rate of optic toxicity was not
observed in other studies including patients who also
received chemotherapy. Therefore, whether the additionof chemotherapy worsens optic toxicity following RT for
sinonasal malignancies is unclear at this time.
IMRT can be challenging at times as no clear consen-
sus exist on how to set the dose constraints for the optic
structures (ON/OC). As previous described, a lower in-
cidence of severe vision impairment has been reported
in 2D/3D studies when the radiation dose to the optic
pathway was kept to ≤ 60 Gy [3-19]. This finding was
again evidenced in the IMRT studies. As an illustration,
Madani et al. reported only 1.4% severe optic toxicity
when < 5% of the optic pathway received more than
60 Gy [22]. The best chance of vision preservation and
the avoidance of severe vision impairment appear to be
associated with keeping the maximal radiation dose to
the optic pathway to approximately 54 Gy or less [3-26].
This is also corroborated by the QUANTEC report on
the radiation dose volume effect on the optic pathway
[46]. However, it may be difficult to obtain if the tumor
is close to the optic apparatus. Other confounding fac-
tors such as the volume of the optic apparatus receiving
high radiation dose, the influence of chemotherapy and
chronic conditions, such as, diabetes mellitus, warrants
further investigation in the future [47]. Altered fraction-
ation has not been shown to be associated with worse
optic toxicity profiles when compared with other studies
in which conventional fractionation is used [5,6,8,9,25].
This is especially true when the fractional dose was only
slightly above 2 Gy [5,25]. pt]?>Thus, the dose volume
effects of altered fractionation schedules with > 2 Gy per
fraction will need to be further characterized in the future
since many studies were conducted in the pre-3D era
Table 6 Techniques of IMRT delivery ± comparison with 2D/3D techniques





IMRT vs. 2D/3D RT 64 Gy/32 frx Contra-lateral
ON Dmax ≤
60 Gy
On average, IMRT decreased the Dmax to the contralateral ON
when compared with 2D & 3D RT(56.4 Gy vs. 65.7 Gy & 64.2 Gy),
and minimized volume receiving <95% prescribed dose (8.5% vs.
15.1% & 14.7%)
Lee [31] Static IMRT vs. 3D CRT 70 Gy/35 frx Dmax ≤ 60 Gy IMRT improved PTV coverage by the dose prescribed in general




Modulator IMRT vs. 3D CRT 60-66 Gy/30–33 frx Dmax ≤ 54 Gy 35% minimal transmission IMRT decreased Dmax to the ON/OC
(p < 0.05), and is comparable to static IMRT in ON/OC sparing
Huang
[33]
15 beam IMRT; Sequential
tomotherapy (MIMic); 5-field 3D
CRT; 3-field 2D RT
Minimal dose of
60 Gy to CTV &
70 Gy to GTV
Dmax ≤ 54 Gy IMRT achieved better GTV coverage & sparing of OC when
compared to 2D & 3D RT
Mock
[34]
Passive scanning PT; IMRT; 3D
CRT; 2D RT
60-70 Gy to the PTV ≤ 50 Gy to
ON/OC
Not significantly different, 3D CRT & IMRT achieved better OAR
sparing than 2D RT. PT decreased OAR mean dose by > 60%
when compared to 3D CRT & IMRT.
Pacholke
[35]
6-7 beam coplanar IMRT; 3 field;
4 field




IMRT did not demonstrate any clear advantage over
conventional 4 field plans.
Claus
[36]
4-11 beam IMRT, 5/9 beam
setups were coplanar
70 Gy/35 frx ≤ 60 Gy Increased beam & segment number and non-coplanar setup
may lead to improved PTV dose coverage and improved OAR
sparing in selected cases.
Wang
[37]
9 beam coplanar IMRT; 5 beam
non-coplanar/coplanar IMRT
63 Gy/35 frx to PTV Dmax < 50 Gy Target dose better, mean dose to both ON & Dmax to the
contralateral ON was significantly lower with the 5 beam
approach.
Serre [38] 5 beam coplanar IMRT; 5 beam
non-coplanar IMRT




7 beam non-coplanar IMRT vs.
HT
50 Gy/25 frx n/a Comparable PTV dose coverage & OAR sparing, although better
sparing of ipsilateral eye & lens
Chen
[40]
9-11 beam coplanar IMRT vs. HT 70 Gy/35 frx Dmax: 54 Gy HT reduced Dmax to OC, ipsilateral ON & retina; improved target
dose homogeneity
Tsien [41] 9 beam coplanar IMRT vs. 3D
CRT
70 Gy/35 frx Dmax ≤ 60 Gy Clinical decision to spare the contralateral ON only can lead to
improved PTV dose coverage and improved TCP when
compared to bilateral ON sparing IMRT and 3D CRT.
ON optic nerve, OC optic chiasm, PTV planning target volume, OAR organs at risk, PT proton therapy, HT helical tomotherapy, frx fraction.
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estimated.
Only small studies on a limited number of patients
have conducted to compare IMRT with non-IMRT tech-
niques, and various IMRT strategies [30-41]. Thus, no
clear demonstration of the superiority of IMRT over 2D/
3D techniques can be made based on these dosimetric
studies. However, increased magnitude of intensity
modulation through increasing the number of segments,
beams, and using a combination of coplanar and non-
coplanar arrangements may help increase dose conform-
ality and optic pathway sparing when IMRT is used to
treat sinonasal malignancies. This is suggested in studies
which demonstrated HT’s superiority over linac-based
coplanar IMRT in target dose homogeneity and optic
structure sparing; but comparable optic pathway sparing
when HT and non-coplanar IMRT were compared
[39,40]. HT’s delivers image guided IMRT with intensity
modulation through 51 equally spaced angles [48]. One
important component of IMRT optimization to treatsinonasal malignancies is the incorporation of clinical de-
cision into the optimization process. As shown by Tsien
et al. decision to spare the contralateral ON only may lead
to improved IMRT plan quality and potentially better
tumor control in certain cases [41].
Conclusion
Dose conformality to the target volume and conformal
avoidance of the organs at risk achieved through IMRT
may provide better local control and less optic toxicity
compared to conventional radiotherapy technique. A
dose of 54 Gy or less delivered with conventional frac-
tionation to the optic apparatus may provide optimal
visual preservation if the tumor is not close to these crit-
ical structures. Further prospective studies with long-
term follow-up should be conducted to assess how best
to preserve vision and improve local control.
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